Radiopharmaceutical Device Development Explained

Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Radiopharmaceutical Device Development Explained

Sector: Diagnostics
Topic: Bio Break
YouTube video thumbnail

Radiopharmaceutical device development is gaining momentum as medical teams explore new frontiers in diagnostic imaging and cancer treatment. In this episode of Bio Break, Nigel and Nick dive into how radioisotopes are used in both therapeutic and imaging applications—and what it means for engineers designing devices that handle radiation safely.

Nigel explains how these radioactive compounds—like radiolabeled glucose—can help detect cancer by highlighting areas of high metabolic activity in the body. The technique is based on how tumors often consume more glucose than surrounding tissue. So when tagged with a tracer like FDG (fluorodeoxyglucose), those hotspots become visible.

Nick shares his own experience using these radiopharmaceuticals in drug delivery trials. He describes a study comparing radiolabeled compounds that either do or do not cross the blood-brain barrier. By using FDG as a positive control and FLT (fluorothymidine) as a negative control, his team was able to track how a drug reached—or failed to reach—the brain.

As device developers, the implications are clear. Designing tools that safely handle radioactive materials requires special care. From the initial generator to the final “daughter” isotopes used in patients, radiopharmaceutical workflows are complex, fast-moving, and full of potential.

For medical device innovators, this space offers exciting opportunities—especially as demand for targeted therapies and precise imaging continues to grow.

96-well lab plates with a red arrow pointing to a green recycling symbol, representing lab plastic recycling for sustainability in medtech.

Nick Allan and Nigel Syrotuck explore the massive volume of single-use plastic in labs and discuss a new company working to close the loop through a circular economy approach.

Nick Allan and Nigel Syrotuck smiling during a Bio Break Book Club episode. Nigel holds the book Why We Sleep by Matthew Walker.

Nick Allan and Nigel Syrotuck share what they have been reading lately. From exploring the science of sleep to diving into change management, their picks show how books can spark insight both inside and outside the lab.

“Hands holding books under the text ‘End-of-Summer Reads,’ highlighting FDA regulatory books and PCR memoirs.

Nick Allan and Nigel Syrotuck share their end-of-summer reading list, featuring FDA regulatory books and PCR memoirs. From navigating regulatory hurdles to celebrating groundbreaking discoveries, their choices show how science reading can be both educational and entertaining.

Pill and vial with arrows over world map. Overlay text reads: ‘Depends where’.

While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.